Prevention of appendicular bone loss in Paget's disease following treatment with intravenous pamidronate disodium

Bone

Volumn 24, Issue 2, 1999, Pages 139-144

  Stewart, G O ^a,e   Gutteridge, D H ^b,e   Price, R I ^c   Ward, L ^b   Retallack, R W ^b   Prince, R L ^b,e   Stuckey, B G A ^b   Kent, G N ^d   Bhagat, C I ^d   Dhaliwal, S S ^b  

^a FREMANTLE HOSPITAL   (Australia)

^b Dept Endocrinol Diabet Sir C ^*  (Australia)

^c SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^d PATHWEST LABORATORY MEDICINE   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Appendicular bone loss; Paget's disease; Pamidronate

Indexed keywords

CALCITRIOL; CALCIUM; PAMIDRONIC ACID; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PAGET BONE DISEASE; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY; CALCITRIOL; CALCIUM, DIETARY; DIPHOSPHONATES; FOREARM; HUMANS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; OSTEITIS DEFORMANS; OSTEOPOROSIS; PARATHYROID HORMONE; TIME FACTORS;

EID: 0032964795     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(98)00163-X     Document Type: Article

References (15)

1. Altman R.D. Long term follow-up of therapy with intermittent etidronate sodium in Paget's disease of bone. Am J Med. 79:1985;583-589.
2. Bekker P., Kylstra J., Altman R., Brown J., Johnston C., Lang R., Mallette L., McClung M., Miller P., Ryan W., Singer F., Siris E., Tucci J., Axelrod D. A multicenter study of risedronate for Paget's disease. J Bone Miner Res. 9:(Suppl. 1):1994;S292.
3. Delmas P.D., Chapuy M.C., Vignon E., Charhon S., Briancon D., Alexandre C., Edouard C., Meunier P.J. Long term effects of dichloromethylene diphosphonate in Paget's disease of bone. J Clin Endocrinol Metab. 54:1982;837-844.
4. Devogelaer J.P., Nagant de Deuxchaisnes C. Treatment of involutional osteoporosis with the bisphosphonate APD (disodium pamidronate) Non-linear increase of lumbar bone mineral density . Christiansen C., et al. Osteoporosis. 1990;1507-1509 Osteopress, Copenhagen.
5. Fenton A.J., Gutteridge D.H., Kent G.N., Price R.I., Retallack R.W., Bhagat C.I., Worth G.K., Thompson R.I., Watson I.G., Barry-Walsh C., Matz L.R. Intravenous aminobisphosphonate in Paget's disease Clinical, biochemical, histomorphometric and radiological responses . Clin Endocrinol. 34:1991;197-204.
6. Fraser W.D., Logue F.C., Gallacher S.J., St. J. O'Reilly D., Beastall G.H., Ralston S.H., Boyle I.T. Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget's disease of bone and hypercalcaemia of malignancy. Bone Miner. 12:1991;113-121.
7. Geusens P., Wouters C., Nijs J., Dequeker J. Effect of the bisphosphonates EHDP and APD on bone mineral density in patients with Paget's disease. Christiansen C., et al. Osteoporosis. 1990;1451-1452 Osteopress, Copenhagen.
8. Gutteridge D.H., Retallack R.W., Ward L.C., Stuckey B.G.A.S., Stewart G.O., Prince R.L., Kent G.N., Bhagat C.I., Price R.I., Nicholson G.C. Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium A 2-year study . Bone. 19:1996;387-394.
9. Harinck H.I.J., Bijvoet O.L.M., Blanksma H.J., Dahlinghaus-Nienhuys P.J. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop. 217:1987;79-98.
10. Khan S.A., Vasikaran S., McCloskey E.V., Benéton M.N.C., Rogers S., Coulton L., Orgee J., Coombes G., Kanis J.A. Alendronate in the treatment of Paget's disease of bone. Bone. 20:1997;263-271.
11. Kivirikko K.I., Laitinen O., Prockop D.J. Modifications of the specific assay for hydroxyproline in urine. Anal Biochem. 19:1967;249-255.
12. Nagant de Deuxchaisnes C., Devogelaer J.P., Esselincks W., Depresseux G., Rombouts-Lindemans C., Huax J.P. Non-hormonal treatment of osteoporosis [letter]. Br Med J. 286:1983;1648.
13. Price R.I., Gutteridge D.H., Stuckey B.G.A., Kent G.N., Retallack R.W., Prince R.L., Bhagat C.I., Johnston C.A., Nicholson G.C., Stewart G.O. Rapid, divergent changes in spinal and forearm bone density following short-term intravenous treatment of Paget's disease with pamidronate disodium. J Bone Miner Res. 8:1993;209-217.
14. Roux C., Gennari C., Farrerons J., Devogelaer J.P., Mulder H., Kruse H.P., Picot C., Titeux L., Reginster J.Y., Dougados M. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum. 38:1995;851-856.
15. Siris E., Weinstein R.S., Altman R., Conte J.M., Favus M., Lombardi A., Lyles K., McIlwain H., Murphy W.A. Jr, Reda C., Rude R., Seton M., Tiegs R., Thompson D., Tucci J.R., Yates A.J., Zimering M. Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab. 81:1996;961-967.